NZ Marine Biotech ($20M MC - High Growth Prospect), page-469

First 469 Last

Share
Profile

Follow
PuntingPennies

434 Posts.

37

11/08/20

14:14

Post #: 46454861
Share

Originally posted by fareki: ↑

As I started this thread, I want to note that I have greatly reduced my position in NZS, partly due to portfolio management practices and being too NZS heavy, but also due to the rocket of a shareprice/fair value of NZS. I feel that the NZS market cap rising $15-20M in the past two days was unjustified for current business activities, I have therefore reduced my holdings by 80%. I believe its falling back down to fair value now, although selling at the oppies equivalent of 7c+ heads was what I saw fit with potential for reentering at a lower price. I believe NZS is due a CR soon, as they have relatively small cash holdings, so I will strongly consider rebuilding my position upon that CR happening.

I remain bullish for NZS prospects following this CR and I remain holding a position in NZS, although as stated in the original post, I was expecting a 5.5c rerate over the next quarter, this far surpassed this expectation, I would be ignoring a large percentage of my financial education by not adjusting my portfolio. I now turn my attention to a company that has just finished a CR and is about to go through a similar rerate and is undervalued. It makes sense to adjust accordingly from NZS to a company such as that. As I still hold a % in NZS I will remain on threads, although I thought it would be honest of me to explain my position.

Cheers guys, alot of us made some serious money over the past 3 weeks. Glad we didnt sell sub 3.

Expand

Thanks Fareki

Are you intending on listening in tomorrow?

NZS Price at posting: 6.2¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

OCC

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

SPR

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

PL3

Patagonia looks to raise $2.15M for South American exploration and development

SRL

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

MSB

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

There are more pages in this discussion • 33 more messages in this thread...

First 469 Last

Add NZS (ASX) to my watchlist

(20min delay)
Last 0.2¢		Change 0.000(0.00%)		Mkt cap ! $3.334M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

NZ Marine Biotech ($20M MC - High Growth Prospect), page-469

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Patagonia looks to raise $2.15M for South American exploration and development

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Featured News

Featured News

NZ Marine Biotech ($20M MC - High Growth Prospect), page-469

Top Stories

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Patagonia looks to raise $2.15M for South American exploration and development

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Featured News

Featured News